Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ALXN2050 in Hepatic Impairment
NCT05259085Phase 1Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point, Maximum (Peak) Steady-state Plasma Concentration and 1 more. Started Apr 2022; status: terminated.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05259085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259085.